Openbookopenbook
Equity
CorMedix Inc(CRMD)
USD --+0.00%
Reward48Moderate
Risk60Medium-High
📊75%Data
Strong 76% profit margin · Revenue growing 810% YoY
CRMD
+0.0 · +0.00%
USD · NASDAQ
CorMedix Inc | Healthcare
Balanced
Market Cap:552.31M
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
60
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CRMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $14.86.

What is CorMedix Inc?

, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

CRMD · Verdict

Moderate reward · elevated risk

CRMD's standout is balance sheet; cash flow and volatility weigh on the picture.

Based on 88% data coverage

CRMD · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet66/100

    Current ratio 3.39

Watchouts 3

  • Cash flow9/100

    -117% free-cash-flow margin

  • Volatility35/100

    Below average

  • Growth45/100

    Rev +510.6% CAGR · earnings -14.0%

Model-based scoring. For information only — not financial advice.

What is CorMedix Inc?

, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 552.31M, and a P/E ratio of 3.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with momentum and profitability offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap552.31M
P/E Ratio3.1719
Dividend YieldN/A
52 Week High17.43
52 Week Low5.6
Last AnnualDecember
IPO Date3/25/2010
IncorporatedUSA
Shares Outstanding79M
No. of Employees64
IndustryBiotechnology
ExchangeNASDAQ
Beta1.298
CurrencyUSD
Websitewww.cormedix.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.